Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?

Article metrics

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Goodson NJ et al. (2002) Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. Arthritis Rheum 46: 2010–2019

  2. 2

    Solomon DH et al. (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107: 1303–1307

  3. 3

    Del Rincon ID et al. (2001) High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 44: 2737–2745

  4. 4

    Hurlimann D et al. (2002) Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 106: 2184–2187

  5. 5

    Branen L et al. (2004) Inhibition of tumor necrosis factor-α reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24: 2137–2142

Download references

Acknowledgements

The synopsis was written by Jasmine Farsarakis, Associate Editor, Nature Clinical Practice.

Author information

Correspondence to Mariana J Kaplan.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kaplan, M. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?. Nat Rev Rheumatol 1, 74–75 (2005) doi:10.1038/ncprheum0066

Download citation

Further reading